Salmon calcitonin: a review of current and future therapeutic indications

被引：159

作者：

Chesnut, C. H., III ^{[1
]}

Azria, M. ^{[2
]}

Silverman, S. ^{[3
]}

Engelhardt, M. ^{[2
]}

Olson, M. ^{[2
]}

Mindeholm, L. ^{[2
]}

机构：

[1] Univ Washington, Osteoporosis Res Grp, Seattle, WA 98195 USA

[2] Novartis Pharma AG, Basel, Switzerland

[3] Cedars Sinai Med Ctr, Dept Med & Rheumatol, Los Angeles, CA 90048 USA

来源：

OSTEOPOROSIS INTERNATIONAL | 2008年 / 19卷 / 04期

关键词：

D O I：

10.1007/s00198-007-0490-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis.

引用

页码：479 / 491

页数：13

共 113 条

[1] Treatment of postmenopausal osteoporosis [J].

Altkorn, D ;

Vokes, T .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (11) :1415-1418

[2]

ARINOVICHE R, 1987, REV MED CHILE, V115, P1039

[3] 25 YEARS OF SALMON-CALCITONIN - FROM SYNTHESIS TO THERAPEUTIC USE [J].

AZRIA, M ;

COPP, DH ;

ZANELLI, JM .

CALCIFIED TISSUE INTERNATIONAL, 1995, 57 (06) :405-408

[4] Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women:: A new potential treatment of osteoarthritis [J].

Bagger, YZ ;

Tankó, LB ;

Alexandersen, P ;

Karsdal, MA ;

Olson, M ;

Mindeholm, L ;

Azria, M ;

Christiansen, C .

BONE, 2005, 37 (03) :425-430

[5] EFFECTS OF CALCITONIN IN PAGETS DISEASE AND POLYOSTOTIC FIBROUS DYSPLASIA [J].

BELL, NH ;

AVERY, S ;

JOHNSTON, CC .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1970, 31 (03) :283-+

[6] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

[7] Analgesic efficacy of calcitonin for vertebral fracture pain [J].

Blau, LA ;

Hoehns, JD .

ANNALS OF PHARMACOTHERAPY, 2003, 37 (04) :564-570

[8] Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club [J].

Boonen, S ;

Body, JJ ;

Boutsen, Y ;

Devogelaer, JP ;

Goemaere, S ;

Kaufman, JM ;

Rozenberg, S ;

Reginster, JY .

OSTEOPOROSIS INTERNATIONAL, 2005, 16 (03) :239-254

[9] Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography [J].

Borah, B ;

Dufresne, TE ;

Chmielewski, PA ;

Johnson, TD ;

Chines, A ;

Manhart, MD .

BONE, 2004, 34 (04) :736-746

[10] THE EFFECT OF RECTAL AND NASAL ADMINISTRATION OF SALMON-CALCITONIN IN NORMAL SUBJECTS [J].

BUCLIN, T ;

RANDIN, JP ;

JACQUET, AF ;

AZRIA, M ;

ATTINGER, M ;

GOMEZ, F ;

BURCKHARDT, P .

CALCIFIED TISSUE INTERNATIONAL, 1987, 41 (05) :252-258

← 1 2 3 4 5 6 7 8 9 10 →